Status:
COMPLETED
Early Stop(Ruling) of the Antibiotic Treatment During Pneumopathies d' Inhalation
Lead Sponsor:
University Hospital, Lille
Conditions:
Aspiration Pneumonia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The two most common consequences resulting from aspiration are chemical pneumonitis and bacterial aspiration pneumonia. Both entities present with comparable clinical signs and symptoms. In the absenc...
Eligibility Criteria
Inclusion
- presence of risk factors for aspiration :
- known or likely swallowing dysfunction,
- altered consciousness,
- cardiac arrest,
- difficult intubation
- witnessed aspiration
- symptoms and signs suggestive of lower respiratory tract pathology
- temperature ≥38.5°C or \<36°C
- leukocyte count ≥10 000/µL or \<1500/µL
- purulent sputum or tracheal aspirate.
- new radiographic infiltrate on chest X-ray
- tracheal intubation and mechanical ventilation since less than 48 hours
Exclusion
- pregnant women
- refuse to participate to the study
- no informed consent
- documented bacteremia
- septic shock
- severe immunosuppression: leukocytes\<1000/L or neutrophils\<500/L, chemotherapy during the last 3 months, organ transplant with chronic immunosuppressors use, HIV (CD4\<50), and chronic corticosteroid use (\>0.5 mg/kg day for at least one month during the last three months).
- moribund patients (SAPS II \>90).
Key Trial Info
Start Date :
September 20 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 22 2024
Estimated Enrollment :
266 Patients enrolled
Trial Details
Trial ID
NCT03763799
Start Date
September 20 2019
End Date
February 22 2024
Last Update
December 23 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Amiens Picardie
Amiens, France
2
Hôpital Roger Salengro, CHU
Lille, France